At the 61st ASH Annual Meeting & Exposition, Naval Daver, MD Anderson Cancer Center, discusses his presentation: Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy.
Questions
1. What are the current therapeutic options for elderly patients with relapsed or refractory AML ineligible for chemotherapy? (0:05)
2. Could you tell us a little about the mechanism of action of idasanutlin? (1:24)
3. What is the rationale for the combination of venetoclax and idasanutlin? (2:50)
4. Could you tell us a little about the phase 1b study and its efficacy and safety findings? (4:36)
5. What progress has been made in identifying biomarkers of response to this combined therapy? (6:30)
Naval Daver has received consulting fees from Abbvie, Genentech, BMS, PFizer, Forty-Seven, DAiichi Sankyo, Astellas, Celgene and Novartis. He has received research funding from Abbvie, Genentech, BMS, PFizer, Forty-Seven, DAiichi Sankyo, Astellas, Celgene and Novartis.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
